Updated:
Ligand Pharmaceuticals
Ligand Pharmaceuticals is a San Diego-based biotechnology asset manager that monetizes drug royalty streams, led by CEO John Higgins.
Ligand Pharmaceuticals
Ligand Pharmaceuticals was founded in 1987 and is headquartered in San Diego. The company is publicly traded under the ticker NASDAQ: LGND and operates as a biotechnology asset manager focused on acquiring and licensing drug royalties. It was originally a drug developer but transitioned to a royalty monetization model in the 2010s. Ligand holds a portfolio of over 100 partnered programs across human and animal health. Asset classes include approved drugs, late-stage clinical candidates, and platform technologies. The firm typically structures deals as upfront payments plus milestone and royalty streams, often co-investing with partners like Bristol Myers Squibb and Novartis to fund development. Notable royalty-bearing assets include Kyprolis, a cancer drug co-developed with Amgen, and Vyleesi for hypoactive sexual desire disorder. The portfolio spans oncology, central nervous system disorders, and infectious diseases, with commercial reach across North America, Europe, and Asia. As of 2023, Ligand reported annual revenue of approximately $135M, primarily from royalties and milestone payments. The company employs a lean team of under 100 people, with no additional offices disclosed beyond San Diego. It maintains no separate philanthropic vehicle or operating-company arm beyond its core licensing operations. In May 2024, Ligand announced a strategic collaboration with Regeneron to develop novel gene therapies for rare diseases (per the firm's press release, May 2024). Ligand's structural differentiator is its pure-play royalty model, which insulates it from drug-development failure risk while still capturing upside from approved therapies. This asset-light architecture allows it to recycle capital into new deals without heavy R&D overhead or manufacturing infrastructure.
General information
Firm type
Asset Manager
Year founded
1987
AUM
Undisclosed
Location
Region
North America
Country
United States
City
San Diego
Corporate office
San Diego, CA, United States
Principals
John L. Higgins
CEO
Matthew W. Foehr
Chairman
Sector focus
Frequently asked questions
How does Ligand Pharmaceuticals generate revenue?
Ligand generates revenue primarily through royalty payments on approved drugs and milestone payments from licensing agreements. It does not manufacture or market drugs itself. The model involves acquiring or co-funding late-stage compounds and then collecting a percentage of future sales (per public financial filings).
What investment stages does Ligand Pharmaceuticals target?
Ligand typically targets late-stage clinical and approved assets. It partners with biotech and pharmaceutical companies to fund development in exchange for royalty streams. This is distinct from venture capital, as Ligand focuses on de-risked compounds with clearer regulatory pathways (per the firm's investor presentations).
Does Ligand Pharmaceuticals manage external capital?
No, Ligand is a publicly traded company (NASDAQ: LGND) that manages its own balance sheet. It does not raise pooled investor capital like a traditional asset manager or family office. Its funding comes from its own cash flow and debt financing (per SEC filings).
Which sectors does Ligand Pharmaceuticals focus on?
Ligand's portfolio concentrates on biotech and pharmaceuticals, specifically oncology, central nervous system disorders, and infectious diseases. It avoids non-healthcare sectors. The firm also has an animal health division, allowing it to diversify within healthcare (per annual reports).
What is the relationship between Ligand Pharmaceuticals and its partners like Bristol Myers Squibb?
Ligand partners with major drug developers through license and co-development agreements. For example, it holds a royalty stream on Kyprolis, co-developed by Amgen and licensed from Ligand. These partnerships typically involve upfront payments, milestones, and ongoing royalties (per the firm's historical filings).
Is Ligand Pharmaceuticals a single-family office?
No, Ligand is a publicly held corporation, not a family office. It is traded on NASDAQ and subjet to SEC reporting requirements. Its business model — collecting royalties from drug licensing — resembles an asset manager but without external client capital (per corporate governance disclosures).
How does Ligand Pharmaceuticals manage risk in its portfolio?
Ligand mitigates risk by diversifying across dozens of partnered programs and multiple therapeutic areas. It avoids drug-development failure risk by focusing on approved or late-stage assets. Additionally, its contracts include milestone payments that create cash flow before final approval (per investor relations materials).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: